2016 ASCO Annual Meeting Abstract 8007: Phase 1/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): A Multiple Myeloma Research Consortium Multicenter Study

KPd is well tolerated and highly active (≥PR 84%) with encouraging PFS (median 12.9 mo) in less pretreated, mostly LEN-refractory and PI-naive/sensitive RRMM in the era of increased use of extended LEN treatment. 


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.